Der onkologische Patient und die ästhetische Medizin

Zusammenfassung

Hintergrund

Mit steigender Zahl an Krebserkrankungen wächst auch die Gruppe der Langzeitüberlebenden, die zunehmend unter den sichtbaren und funktionellen Folgen onkologischer Therapien leiden. Neben den somatischen Belastungen rücken psychosoziale Faktoren wie Selbstwahrnehmung und Lebensqualität in den Fokus der Versorgung.

Ziel

Ziel dieser Arbeit ist es, die Bedeutung ästhetisch-medizinischer Verfahren in der Betreuung onkologischer Patienten darzustellen und deren Potenzial zur Verbesserung von Lebensqualität, Selbstbild und sozialer Teilhabe zu beleuchten.

Methoden

Anhand aktueller Literatur sowie klinischer Erfahrungswerte werden die häufigsten therapieassoziierten Hautveränderungen aufgeführt und die Anwendung ästhetischer Interventionen wie Botulinumtoxin und dermaler Filler bei onkologischen Patienten kritisch dargestellt. Dabei werden indikationsspezifische Aspekte, Kontraindikationen und besondere Vorsichtsmaßnahmen diskutiert.

Ergebnisse

Ästhetische Behandlungen können bei sorgfältiger Indikationsstellung und enger interdisziplinärer Abstimmung sicher durchgeführt werden. Sie bieten effektive Unterstützung bei der Linderung therapiebedingter Veränderungen wie Narbenbildung, Alopezie oder Volumenverlust. Gleichzeitig bestehen onkologiespezifische Risiken, etwa durch Immunsuppression, Medikamenteninteraktionen und potenzielle immunologische Reaktionen.

Diskussion

Die ästhetische Medizin kann einen wertvollen Beitrag zur ganzheitlichen Betreuung onkologischer Patienten leisten. Ihre Integration in die supportive und rehabilitative Versorgung sollte strukturell verankert und weiter wissenschaftlich evaluiert werden.

Abstract

Background

With the rising incidence of cancer, the number of long-term survivors is also increasing. These individuals are often affected by visible and functional consequences of oncological therapies. In addition to somatic burdens, psychosocial factors such as self-perception and quality of life are gaining importance in patient care.

Objective

This article aims to highlight the relevance of aesthetic medical procedures in the management of oncology patients and to explore their potential in improving quality of life, body image, and social reintegration.

Methods

Based on current literature and clinical experience, the most common therapy-associated skin changes are presented. The application of aesthetic interventions such as botulinum toxin and dermal fillers in cancer patients is critically discussed, with a focus on indication-specific considerations, contraindications, and special precautions.

Results

When carefully indicated and coordinated within an interdisciplinary framework, aesthetic treatments can be performed safely. They provide effective support in alleviating therapy-related changes such as scarring, alopecia, or volume loss. However, oncology-specific risks must be considered, including immunosuppression, drug interactions, and potential immunological reactions.

Discussion

Aesthetic medicine can make a valuable contribution to the holistic care of cancer patients. Its integration into supportive and rehabilitative care should be structurally established and further scientifically evaluated.

Schlüsselwörter

Ästhetische Medizin - onkologische Patienten - Lebensqualität - Botulinumtoxin - Filler

Keywords

aesthetic medicine - oncology patients - quality of life - botulinum toxin - fillers

Publication History

Received: 09 September 2025

Accepted after revision: 19 January 2026

Article published online:
13 February 2026

• Literatur

• 1 Bray F, Laversanne M, Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263
• 2 Zebolsky AL, Patel N, Heaton CM. et al. Patient-Reported Aesthetic and Psychosocial Outcomes After Microvascular Reconstruction for Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2021; 147: 1035-1044
• 3 Sebri V, Pizzoli SFM, Marzorati C. et al. Interoception and body image in breast cancer patients: a mindfulness-based stress reduction protocol. Front Psychol 2014; 15: 1394355
• 4 Haylock PJ. Cancer survivorship advocacy. Semin Oncol Nurs 2015; 31: 79-85
• 5 Groenvold M. Health-related quality of life in early breast cancer. Dan Med Bull 2010; 57: B4184
• 6 Sonnenschein C, Soto AM. Over a century of cancer research: inconvenient truths and promising leads. PLoS Biol 2020; 18: e3000670
• 7 Brahmer JR, Abu-Sbeih H, Ascierto PA. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021; 9: e002435
• 8 Keenan LG, Lavan N, Dunne M. et al. Modifiable risk factors for acute skin toxicity in adjuvant breast radiotherapy: Dosimetric analysis and review of the literature. Med Dosim 2019; 44: 51-55
• 9 Seitschek D, Sulz-Lehar N, Sebesta C. Psychoonkologie – Bestandteil einer umfassenden onkologischen Behandlung [Psychooncology-part of a comprehensive oncological treatment]. Wien Med Wochenschr 2023; 173: 206-208
• 10 Schulze JB, Günther MP, Riemenschnitter C. et al. Distinct psycho-oncological support inclinations and needs in patients with cancer: A large sample latent class analysis approach. Gen Hosp Psychiatry 2022; 75: 17-22
• 11 Drageset J, Sandvik RK, Eide LSP. et al. Quality of life among cancer inpatients 80 years and older: a systematic review. Health Qual Life Outcomes 2021; 19: 98
• 12 Matheson D, Abdel-Aty H, O'Shea L. Quality of Life Measurements from the Patient Perspective: Capturing the Heterogeneity of the Patient Experience in a Standardised Way. Eur Urol Focus 2023; 9: 425-426
• 13 Kołodziejczyk A, Pawłowski T. Negative body image in breast cancer patients. Adv Clin Exp Med 2019; 28: 1137-1142
• 14 Bowie J, Brunckhorst O, Stewart R. et al. Body image, self-esteem, and sense of masculinity in patients with prostate cancer: a qualitative meta-synthesis. J Cancer Surviv 2022; 16: 95-110
• 15 Cotofana S, Sattler S, Frank K. et al. Aesthetic medicine-Quo Vadis?. J Cosmet Dermatol 2022; 21: 6526-6527
• 16 Álvarez-Pardo S, De Paz JA, Montserrat Romero-Pérez E. et al. Factors Associated with Body Image and Self-Esteem in Mastectomized Breast Cancer Survivors. Int J Environ Res Public Health 2023; 20: 5154
• 17 World Health Organization. Constitution of the world health organization (2014) Basic Documents. 48th ed.. Genevia: 2014
• 18 Krueger N, Luebberding S, Sattler G. et al. The history of aesthetic medicine and surgery. J Drugs Dermatol 2013; 12: 737-742
• 19 Rossi AM, Hibler BP, Navarrete-Dechent C. et al. Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. J Am Acad Dermatol 2021; 85: 693-707
• 20 Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol 2018; 19 (Suppl. 1) 31-39
• 21 Cicchetti A, Mangili P, Fodor A. et al. Skin dose-volume predictors of moderate-severe late side effects after whole breast radiotherapy. Radiother Oncol 2024; 194: 110183
• 22 Alvarez-Pardo S, Romero-Pérez EM, Camberos-Castañeda N. et al. Quality of Life in Breast Cancer Survivors in Relation to Age, Type of Surgery and Length of Time since First Treatment. Int J Environ Res Public Health 2022; 19: 16229
• 23 Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011; 65: 624-635
• 24 Yamada T, Ishihara S, Kawai M. et al. Analysis of late adverse events and their chronological changes after radiation therapy for cervical cancer. Nagoya J Med Sci 2018; 80: 487-496
• 25 Salah S, Kerob D, Pages Laurent C. et al. Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's Adverse Event Reporting System dataset. J Am Acad Dermatol 2024; 91: 863-871
• 26 Grenda T, Grenda A, Krawczyk P. et al. Botulinum toxin in cancer therapy-current perspectives and limitations. Appl Microbiol Biotechnol 2022; 106: 485-495
• 27 Pinto C, Barone CA, Girolomoni G. et al. Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy: Update of the Italian Expert Recommendations. Am J Clin Oncol 2016; 39: 407-415
• 28 Ryan AM, Prado CM, Sullivan ES. et al. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 2019; 67–68: 110539
• 29 Nekhlyudov L, Mollica MA, Jacobsen PB. Developing a Quality of Cancer Survivorship Care Framework: Implications for Clinical Care, Research, and Policy. J Natl Cancer Inst 2019; 111: 1120-1130
• 30 Tejero P, Pinto H. Aesthetic Treatments for the Oncology Patient. 1st ed.. CRC Press; 2020
• 31 Brin MF, Burstein R. Botox (onabotulinumtoxinA) mechanism of action. Medicine (Baltimore) 2023; 102 (Suppl. 1) e32372
• 32 Polo M. Botulinum Toxin and Smile Design. Dent Clin North Am 2022; 66: 419-429
• 33 Kroumpouzos G, Kassir M, Gupta M. Complications of botulinum toxin A: an update review. J Cosmet Dermatol 2021; 20: 1585-1590
• 34 Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins 2019; 11: 491
• 35 Proietti I, Skroza N, Mambrin A. et al. Aesthetic Treatments in Cancer Patients. Clin Cosmet Investig Dermatol 2021; 14: 1831-1837
• 36 Brin MF. Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine. Medicine (Baltimore) 2023; 102 (Suppl. 1) e32370
• 37 Farham F, Onan D, Martelletti P. Non-Migraine Head Pain and Botulinum Toxin. Toxins (Basel) 2014; 16: 431
• 38 Carter D, Dickman R. The Role of Botox in Colorectal Disorders. Curr Treat Options Gastroenterol 2018; 16: 541-547
• 39 Nieri CA, Benaim EH, Zhang YH. et al. Botox for the prevention of radiation-induced Sialadenitis and xerostomia in head and neck cancer patients: A pilot study. Head Neck 2023; 45: 2198-2206
• 40 Talotta R, Rucci F, Canti G. et al. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Immunotherapy 2019; 11: 241-254
• 41 Itani M, Goldman Gollan Y, Ezell K. et al. Thymoma and Myasthenia Gravis: An Examination of a Paraneoplastic Manifestation. Cureus 2023; 15: e34828
• 42 Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004; 22: 66-75
• 43 Ansiaux R, Baudelet C, Cron GO. et al. Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin Cancer Res 2006; 12: 1276-1283
• 44 Bass LS. Injectable Filler Techniques for Facial Rejuvenation, Volumization, and Augmentation. Facial Plast Surg Clin North Am 2015; 23: 479-488
• 45 Struik GM, Godart J, Verduijn GM. et al. A randomized controlled trial testing a hyaluronic acid spacer injection for skin toxicity reduction of brachytherapy accelerated partial breast irradiation (APBI): a study protocol. Trials 2018; 19: 689
• 46 Quach B, Clevens RA. Complications of Injectables. Atlas Oral Maxillofac Surg Clin North Am 2024; 32: 57-63
• 47 Kim B, Somia N. Herpes reactivation after injection of dermal fillers. ANZ J Surg 2013; 83: 998
• 48 Haneke E. Adverse effects of fillers. Dermatol Ther 2019; 32: e12676
• 49 Davidson T, Druyan A, Goshen E. et al. The PET-CT Radiological Appearance of Facial Cosmetic Injections: A Pitfall in the Evaluation of the Oncological Patient. Isr Med Assoc J 2017; 19: 679-681
• 50 Falcón González A, Gallegos Sancho MI. et al. Beyond cancer treatment: dermo-aesthetic and other wellness recommendations for breast cancer patients. Clin Transl Oncol 2025; 27: 909-934
• 51 Shamban A. Safety and efficacy of facial rejuvenation with small gel particle hyaluronic acid with lidocaine and A botulinum toxin A in post-chemotherapy patients: a Phase IV Investigator-initiated Study. J Clin Aesthet Dermatol 2024; 7: 31-36
• 52 Sung Y, Kim MH, Cho E. Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate. J Cosmet Laser Ther 2019; 21: 243-244
• 53 Wongprasert P, Dreiss CA, Murray G. Evaluating hyaluronic acid dermal fillers: A critique of current characterization methods. Dermatol Ther 2022; 35: e15453
• 54 Dhaliwal P, Ibad S, Losak D. et al. A case of granulomatous hypersensitivity reactions to a dermal filler precipitated by PD-1 checkpoint inhibitor therapy. SKIN J Cutan Med 2021; 5: 41-45